Eisai Co., Ltd. (TYO:4523)
Japan · Delayed Price · Currency is JPY 5,137.00
+125.00 (2.49%)
Sep 5, 2025, 3:30 PM JST
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
73.56M JPY
Profits / Employee
4.61M JPY
Market Cap
1,448.06B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 10,917 | -150 | -1.36% |
| Mar 31, 2024 | 11,067 | -9 | -0.08% |
| Mar 31, 2023 | 11,076 | -246 | -2.17% |
| Mar 31, 2022 | 11,322 | 85 | 0.76% |
| Mar 31, 2021 | 11,237 | 239 | 2.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 5,026 |
| Takeda Pharmaceutical Company | 47,455 |
| HOYA Corporation | 37,909 |
| Daiichi Sankyo Company | 19,765 |
| Otsuka Holdings | 35,338 |
| Astellas Pharma | 13,643 |
| Shionogi & | 4,955 |
| Olympus | 29,297 |
Eisai News
- 3 days ago - Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 - PRNewsWire
- 4 days ago - Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose - Seeking Alpha
- 4 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. ... - GuruFocus
- 4 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Benzinga
- 4 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - PRNewsWire
- 8 days ago - US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters
- 8 days ago - FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment - Investor's Business Daily
- 13 days ago - Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news - GuruFocus